Skip to main content

Table 1 Patient characteristics and clinical history at baseline

From: Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014)

 

Present study

Registration study

Number of patients (N)

217

253

Gender, n (%)

 Male

183 (84)

NR

 Female

34 (16)

NR

Age, years

 Median (IQR)

69 (62–76)

NR

  < 65, n (%)

73 (34)

135 (53)

  ≥ 65, n (%)

144 (66)

118 (47)

ECOG PS, n (%)

 0

101 (47)

72 (28)

 1

100 (46)

181 (72)

  ≥ 2

16 (7)

0 (0)

Creatinine clearance, n (%)

  > 60

125 (58)

134 (54)

 40–60

75 (35)

104 (42)

  < 40

17 (8)

10 (4)

Number of metastatic sites, n (%)

 1 site

127 (58)

62 (25)

  ≥ 2 sites

90 (42)

191 (75)

Visceral involvement, n (%)

115 (53)

187 (74)

Metastatic sites, n (%)

 Lymph nodes only

103 (47)

NR

 Liver

47 (22)

NR

 Lungs

70 (32)

NR

 Bone

79 (36)

NR

 Brain

2 (1)

NR

 Other tissue (not visceral)

32(15)

NR

Prior pelvic irradiation, n (%)

16 (7)

57 (23)

Prior therapy with platinum-based regimen, n (%)

 Cisplatin

122 (56)

164 (65)

 Carboplatin

91 (42)

75 (30)

 Other platinum combination

4 (2)

14 (5)

  1. ECOG PS Eastern Cooperative Oncology Group Performance Status, IQR interquartile range, NR not reported